@entity6 in XXXX : direct medical costs of major @entity532 .

@entity1 @entity64 @entity6 @entity532 @entity3394 @entity2412 @entity583 @entity385
OBJECTIVES: To estimate direct medical costs of managing major @entity532 in @entity6 @entity1 . METHODS: Costs were estimated for @entity583 ( @entity583 ) and @entity385 by applying unit costs to typical resource use profiles. Data were obtained from many Canadian sources, including the Ontario Case Cost Project, provincial physician and laboratory fee schedules, provincial formularies, government reports, and peer-reviewed literature. For each complication, the event costs per @entity1 are those associated with resource use specific to the acute episode and any subsequent care occurring in the first year. State costs are the annual costs per @entity1 of continued management. All costs are expressed in 1996 Canadian dollars. RESULTS: Acute hospital care accounts for approximately half of the first year management costs ( 15,125) of @entity583 . Given the greater need for postacute care, acute hospital care has less impact (28%) on event costs for @entity64 ( 31,076). The state costs for @entity583 and @entity64 are  1544 and  8141 per @entity1 , respectively. CONCLUSIONS: Macrovascular complications of @entity6 potentially represent a substantial burden to @entity3394 's health care system. As new therapies emerge that may reduce the incidence of some @entity2412 , decision makers will need information to make critical decisions regarding how to spend limited health care dollars. Published literature lacks Canadian-specific cost estimates that may be readily translated into @entity1 -level cost inputs for an economic model. This paper provides two key pieces of the many needed to understand the scope of the economic burden of @entity6 and its complications for @entity3394 .
